Fiboflapon

DB06346InvestigationalSmall molecule

Investigated for use/treatment in inflammatory disorders (unspecified).

Mechanism: FLAP (5-Lipoxygenase Activating Protein) is a key component early in the leukotriene pathway, a complex signaling process that exerts control over biological processes, such as inflammation and immunity. Excessive production of leukotrienes exacerbates inflammatory diseases, such as asthma; the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke. AM803 binds to FLAP, inhibiting the synthesis of leukotrienes that cause inflammation. [Amira Pharmaceuticals Website]
Curator reviewed
Primary indication: Investigated for use/treatment in inflammatory disorders (unspecified).Curator reviewed
Formula / weight: C₃₈H₄₃N₃O₄S · 637.84 g/mol (avg)
Code names: AM-803 · GSK-2190915

Resolves to

Compound

Structure

InChIKeyDFQGDHBGRSTTHX-UHFFFAOYSA-NSMILESCCOC1=CC=C(C=N1)C1=CC=C(CN2C(CC(C)(C)C(O)=O)=C(SC(C)(C)C)C3=CC(OCC4=CC=C(C)C=N4)=CC=C23)C=C1

Targets

What you can answer from here — as of September 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fiboflapon, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.